• linkedin
  • Increase Font
  • Sharebar

    RT-ADT combo may boost pN1 prostate cancer survival

    Study findings suggest undertreatment among men with pathologic node-positive disease

     

    5-year overall survival rates compared

    Median follow-up for the group was 48 months. Findings of an unadjusted Kaplan-Meier analysis showed 5-year overall survival rates in the observation, RT plus ADT, RT, and ADT groups were 85.7%, 88%, 89.5%, and 83%, respectively. The differences comparing the RT plus ADT and RT groups with both the observation- and ADT-only cohorts were statistically significant.

    Read: Fusion Bx-guided HIFU shows promise in localized PCa

    Comparisons between groups showed statistically significant differences in Charlson Comorbidity Index scores, extent of the pelvic lymph node dissection, Gleason grade distribution, T stage, number of lymph nodes examined, number of positive lymph nodes, and presence of positive margins. In a Cox regression analysis adjusting for these differences, RT plus ADT was associated with significantly longer overall survival compared with all other groups.

    The authors also performed a logistic regression analysis to determine patient and disease characteristics associated with treatment selection. They found that younger patients and those who were healthier (Charlson Comorbidity Index=0) or who had positive margins, higher Gleason score, locally advanced tumors (pT3b or pT4 disease), or had underwent limited lymph node dissection (five or fewer nodes examined) were most likely to undergo subsequent RT plus ADT rather than be followed with observation or ADT alone.

    More from Urology Times:

    Model unable to identify focal therapy candidates

    Men must be entitled to PCa screening, treatment choice

    Side effects of modern PCa treatments compared


    Subscribe to Urology Times to get monthly news from the leading news source for urologists.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll